Forte Biosciences, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Forte Biosciences, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q3 2024.
  • Forte Biosciences, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$8.39M, a 15.7% increase year-over-year.
  • Forte Biosciences, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$34.2M, a 12.2% decline year-over-year.
  • Forte Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$31.5M, a 127% decline from 2022.
  • Forte Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$13.9M, a 36.1% increase from 2021.
  • Forte Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$21.7M, a 53.3% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$34.2M -$8.39M +$1.56M +15.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$35.8M -$12.5M -$3.62M -40.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$32.1M -$7.42M -$667K -9.88% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$31.5M -$5.87M -$995K -20.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$30.5M -$9.96M -$6.56M -193% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$23.9M -$8.9M -$5.86M -193% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$18.1M -$6.75M -$4.19M -163% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$13.9M -$4.88M -$1.54M -46% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$12.3M -$3.4M +$4.35M +56.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$16.7M -$3.04M +$2.78M +47.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$19.5M -$2.57M +$2.24M +46.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$21.7M -$3.34M +$1.24M +27% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$22.9M -$7.75M -$2.65M -52% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$20.3M -$5.81M +$28.9M +83.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$49.2M -$4.8M -$2.75M -134% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$46.5M -$4.58M +$6.01M +56.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$52.5M -$5.1M -$4.41M -639% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$48.1M -$34.8M -$34.1M -5418% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$14M -$2.05M -$865K -73% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$13.1M -$10.6M +$9.02M +46% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-27
Q3 2019 -$22.1M -$690K -$307K -80.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$21.8M -$630K +$15.5M +96.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-09
Q1 2019 -$37.3M -$1.19M +$11.7M +90.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-09
Q4 2018 -$49M -$19.6M -$8.77M -80.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$40.2M -$383K +$9.57M +96.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$49.8M -$16.1M -$7.02M -77.5% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$42.7M -$12.9M -$3.81M -42% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$38.9M -$10.8M -$2.41M -28.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$36.5M -$9.95M -$953K -10.6% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 -$35.6M -$9.07M -$1.02M -12.7% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 -$34.5M -$9.07M -$1.07M -13.3% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27
Q4 2016 -$33.5M -$8.43M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-09
Q3 2016 -$9M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-09
Q2 2016 -$8.04M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-09
Q1 2016 -$8.01M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.